Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C37H48N6O5S2 |
Molecular Weight | 720.944 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4
InChI
InChIKey=NCDNCNXCDXHOMX-XGKFQTDJSA-N
InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1
Molecular Formula | C37H48N6O5S2 |
Molecular Weight | 720.944 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.rxlist.com/norvir-drug.htm
https://www.drugs.com/mtm/ritonavir.html
http://www.wikidoc.org/index.php/Ritonavir
Curator's Comment: description was created based on several sources, including:
http://www.rxlist.com/norvir-drug.htm
https://www.drugs.com/mtm/ritonavir.html
http://www.wikidoc.org/index.php/Ritonavir
Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Ritonavir binds to the protease active site and inhibits the activity of the enzyme. It is FDA approved for the treatment of HIV-1 infection. In patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving Ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. The most frequently reported adverse drug reactions among patients receiving Ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paresthesia and oral paresthesia), rash, and fatigue/asthenia.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14634041 | https://www.ncbi.nlm.nih.gov/pubmed/9107549
Curator's Comment: Known to be CNS penetrant in guinea pig and rats. Human data not available.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4729 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11159797 |
2.2 µM [IC50] | ||
Target ID: CHEMBL2364675 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10952482 |
0.14 µM [IC50] | ||
Target ID: CHEMBL243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17627597 |
0.01 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NORVIR Approved UseKALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. The following points should be considered when initiating therapy with KALETRA: The use of other active agents with KALETRA is associated with a greater likelihood of treatment response [see Clinical Pharmacology (12.4) and Clinical Studies (14) Launch Date8.2563839E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.2 μg/mL |
600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
RITONAVIR unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
129 μg × h/mL |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
RITONAVIR unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5 h |
600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
RITONAVIR unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
RITONAVIR unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 1 times / day steady, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: |
healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: |
Disc. AE: Death fetal... AEs leading to discontinuation/dose reduction: Death fetal (1 patient) Sources: |
50 mg 1 times / day steady, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: |
healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: |
Disc. AE: Hypertension... AEs leading to discontinuation/dose reduction: Hypertension (grade 2, 1 patient) Sources: |
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: |
Other AEs: Gastrointestinal disorder NOS, Lipids abnormal... Other AEs: Gastrointestinal disorder NOS Sources: Lipids abnormal Insulin resistance Lipoatrophy |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Death fetal | 1 patient Disc. AE |
200 mg 1 times / day steady, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: |
healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: |
Hypertension | grade 2, 1 patient Disc. AE |
50 mg 1 times / day steady, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: |
healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: |
Gastrointestinal disorder NOS | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: |
|
Insulin resistance | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: |
|
Lipids abnormal | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: |
|
Lipoatrophy | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
Sources: https://dmd.aspetjournals.org/content/26/6/552 Page: - |
yes [Km 0.05 uM] | |||
Sources: https://dmd.aspetjournals.org/content/26/6/552 Page: - |
yes [Km 0.21 uM] | |||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
PubMed
Title | Date | PubMed |
---|---|---|
Protease inhibitors shine in triple combinations. | 1996 Mar |
|
Saquinavir soft gelatin capsule: a comparative safety review. | 2001 |
|
Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir. | 2001 |
|
Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. | 2001 Apr |
|
Vertical HIV-1 transmission: prophylaxis and paediatric follow-up. | 2001 Apr |
|
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial. | 2001 Apr |
|
Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen. | 2001 Apr 1 |
|
Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs. | 2001 Apr 10 |
|
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. | 2001 Apr 13 |
|
Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography. | 2001 Apr 13 |
|
Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology. | 2001 Apr 15 |
|
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. | 2001 Apr 15 |
|
A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. | 2001 Apr 15 |
|
Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of HIV viral dynamic parameters. | 2001 Apr 15 |
|
[An option even for patients with multiple pretreatment]. | 2001 Apr 2 |
|
[Overcoming weaknesses in therapy. Protease inhibitors with high IQ]. | 2001 Apr 2 |
|
[Possible complication of HIV therapy. Protease inhibitor-induced femur head necrosis]. | 2001 Apr 2 |
|
[Improving the pharmacokinetics of protease inhibitors in a more innovative manner. HIV drugs administered in a more clever way]. | 2001 Apr 2 |
|
[No resistance even after 1 year. New drug combination against HIV]. | 2001 Apr 2 |
|
[Indinavir-ritonavir combination: pharmacologic results and tolerance in patients infected by HIV]. | 2001 Apr 21 |
|
Antiviral drugs: current state of the art. | 2001 Aug |
|
Pharmacology and clinical experience with saquinavir. | 2001 Feb |
|
Use of HIV protease inhibitors as pharmacoenhancers. | 2001 Feb |
|
New developments in anti-HIV chemotherapy. | 2001 Jan-Feb |
|
CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART. | 2001 Jul |
|
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. | 2001 Jun |
|
Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. | 2001 Jun |
|
Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. | 2001 Jun 1 |
|
The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study. | 2001 Jun 1 |
|
Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. | 2001 Jun 1 |
|
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography. | 2001 Jun 15 |
|
Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin. | 2001 Jun 15 |
|
The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. | 2001 Jun 15 |
|
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). | 2001 Jun 15 |
|
A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. | 2001 Mar |
|
Severe bleeding complications in HIV-positive haemophiliac patients treated with protease inhibitors. | 2001 Mar 26 |
|
[HIV: a guide on management of seropositive patients]. | 2001 Mar 3 |
|
ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis. | 2001 Mar 30 |
|
Lopinavir/ritonavir. | 2001 Mar-Apr |
|
Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine. | 2001 May |
|
Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors. | 2001 May |
|
P1/P1' modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays. | 2001 May |
|
A potential role for interleukin-7 in T-cell homeostasis. | 2001 May 15 |
|
Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy. | 2001 May 25 |
|
Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. | 2001 May 25 |
|
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. | 2001 May 25 |
|
Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. | 2001 May 25 |
|
Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. | 2001 May 4 |
|
[Effective in HIV: dual combination with indinavir and ritonavir]. | 2001 May 4 |
|
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography. | 2001 May 5 |
Patents
Sample Use Guides
600 mg twice-day with meals.
Ritonavir should be started at no less than 300 mg twice daily and increased at 2 to 3 day intervals by 100 mg twice daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12964850
Ritonavir diminished the growth rate of Candida albicans as well as the activity of its secreted aspartyl proteinases (Saps) in a nitrogen-limited medium, yeast carbon base and bovine serum albumin (YCB-BSA). This inhibition occurred in a dose-dependent fashion; with 8 mg/l of ritonavir a partial growth inhibition (44%) was produced.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:59:32 UTC 2023
by
admin
on
Wed Jul 05 22:59:32 UTC 2023
|
Record UNII |
O3J8G9O825
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
NBK548747
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
WHO-ATC |
J05AR10
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
WHO-ATC |
J05AE03
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
WHO-VATC |
QJ05AE03
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
WHO-VATC |
QJ05AR10
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
WHO-ATC |
J05AP52
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
LOPINAVIR (AUHTORIZED: HIV INFECTIONS)
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
WHO-ATC |
J05AX66
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
FDA ORPHAN DRUG |
549816
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
NCI_THESAURUS |
C97366
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
FDA ORPHAN DRUG |
509215
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.3
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
KALETRA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.3 (LPV/R)
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
WHO-ATC |
J05AR23
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
WHO-ATC |
J05AP53
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
NDF-RT |
N0000191001
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
NDF-RT |
N0000175889
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
FDA ORPHAN DRUG |
484715
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
NDF-RT |
N0000000246
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
VIEKIRAX (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
WHO-ATC |
J05AX67
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
NORVIR (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
RITONAVIR
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | Description: A white or almost white powder. Solubility: Practically insoluble in water, freely soluble in methanol R, sparingly soluble in acetone R and very slightly soluble in acetonitrile R. Category: Antiretroviral (Protease Inhibitor). Storage: Ritonavir should be kept in a well-closed container, protected from light. Additional information: Ritonavir may exhibit polymorphism. Requirements: Ritonavir contains not less than 98.5 % and not more than 101.0 % of C37H48N6O5S2, calculated with reference to the dried substance. | ||
|
O3J8G9O825
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
CHEMBL163
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
1604803
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
7449
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
SUB10342MIG
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
RITONAVIR
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
85762
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | RxNorm | ||
|
N0000182137
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | Cytochrome P450 2D6 Inhibitors [MoA] | ||
|
N0000182141
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | Cytochrome P450 3A4 Inhibitors [MoA] | ||
|
N0000187064
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | Cytochrome P450 2B6 Inducers [MoA] | ||
|
DB00503
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
D019438
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
Ritonavir
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
N0000185607
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | Cytochrome P450 2C19 Inducers [MoA] | ||
|
2391
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
N0000191266
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | Cytochrome P450 1A2 Inducers [MoA] | ||
|
100000089167
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
N0000190113
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | Breast Cancer Resistance Protein Inhibitors [MoA] | ||
|
45409
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
N0000185507
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | Cytochrome P450 2C9 Inducers [MoA] | ||
|
DTXSID1048627
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
N0000190117
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | UDP Glucuronosyltransferases Inducers [MoA] | ||
|
N0000190118
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | Cytochrome P450 3A Inducers [MoA] | ||
|
693184
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
O3J8G9O825
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
M9636
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | Merck Index | ||
|
N0000190114
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | Cytochrome P450 3A Inhibitors [MoA] | ||
|
392622
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
7160
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
8804
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
C1609
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
155213-67-5
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | |||
|
N0000185503
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY | P-Glycoprotein Inhibitors [MoA] | ||
|
GG-103
Created by
admin on Wed Jul 05 22:59:32 UTC 2023 , Edited by admin on Wed Jul 05 22:59:32 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
METABOLIC ENZYME -> INHIBITOR |
POTENT
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INDUCER | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> INHIBITOR |
POTENT
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> INHIBITOR |
POTENT
|
||
|
TRANSPORTER -> INDUCER |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MINOR
|
||
|
METABOLITE INACTIVE -> PARENT |
MINOR
FECAL
|
||
|
METABOLITE ACTIVE -> PARENT |
37.3% in feces
30.4% in urine
MAJOR
FECAL; URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
FECAL
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
Mixture of BOC-aminoalcohol and isobutoxycarbonyl aminoalcohol- 0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
Mixture of ureidovaline and N-deacylvaline ritonavir-0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
Mixture of BOC-aminoalcohol and isobutoxycarbonyl aminoalcohol-0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
Mixture of ureidovaline and N-deacylvaline ritonavir-0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||